Original Research Article| Volume 104, ISSUE 1, P67-72, July 2021

“It was close enough, but it wasn't close enough”: A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care



      To understand how obtaining a medication abortion by mail with telemedicine counseling versus traditional in-clinic care impacted participants’ access to care.

      Study design

      We conducted a qualitative study with semi-structured telephone interviews with individuals who completed a medication abortion by mail through the TelAbortion study. We asked participants how they learned about telemedicine abortion, reasons for choosing it, what their alternative would have been, and about their experience. We transcribed, coded, and performed qualitative content analysis of the interviews and are presenting a subset of themes related to access to care when the restrictions on clinic dispensing of mifepristone are removed.


      We interviewed 45 people from January to July 2020. Direct-to-patient telemedicine abortion was more convenient and accessible than in-clinic abortion care when considering the burdens of travel, clinic availability, logistics, and cost that were associated with in-clinic abortion. Stigma led to a prioritization of privacy, and by going to a clinic, participants feared a loss of privacy whereas obtaining a medication abortion by mail made it easier to maintain confidentiality. Faced with these barriers, 13% of participants stated they would have continued their pregnancy if TelAbortion had not been an option. Participants found direct-to-patient telemedicine abortion to be acceptable and recommended it to others. Benefits of telemedicine were amplified during the COVID-19 pandemic due to concerns around infection exposure with in-clinic care.


      Going to a clinic was a burden for participants, to the point where some would not have otherwise been able to get an abortion. Medication abortion by mail with telemedicine counseling was a highly acceptable alternative.


      Medication abortion by mail can increase access to abortion with the added benefits of increased perceived privacy and decreased logistical burdens. Removing the in-person dispensing requirement for mifepristone would allow direct-to-patient telemedicine abortion to be implemented outside of a research setting without compromising the patient experience.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Raymond EG
        • Shannon C
        • Weaver MA
        • Winikoff B.
        First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
        Contraception. 2013; 87: 26-37
        • Grossman D
        • Grindlay K.
        Safety of medical abortion provided through telemedicine compared with in person.
        Obstet Gynecol. 2017; 130: 778-782
        • Hyland P
        • Raymond EG
        • Chong E.
        A direct-to-patient telemedicine abortion service in Australia: retrospective analysis of the first 18 months.
        Aust N Z J Obstet Gynaecol. 2018; 58: 335-340
        • Aiken ARA
        • Digol I
        • Trussell J
        • Gomperts R.
        Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland.
        BMJ. 2017; 357: j2011
        • Endler M
        • Lavelanet A
        • Cleeve A
        • Ganatra B
        • Gomperts R
        • Gemzell-Danielsson K.
        Telemedicine for medical abortion: a systematic review.
        BJOG. 2019; 126: 1094-1102
        • Aiken ARA
        • Johnson DM
        • Broussard K
        • Padron E.
        Experiences of women in Ireland who accessed abortion by travelling abroad or by using abortion medication at home: a qualitative study.
        BMJ Sex Reprod Health. 2018; 44: 181-186
        • Endler M
        • Beets L
        • Gemzell Danielsson K
        • Gomperts R
        Safety and acceptability of medical abortion through telemedicine after 9 weeks of gestation: a population-based cohort study.
        BJOG. 2019; 126: 609-618
        • Grossman D
        • Grindlay K
        • Buchacker T
        • Lane K
        • Blanchard K.
        Effectiveness and acceptability of medical abortion provided through telemedicine.
        Obstet Gynecol. 2011; 118: 296-303
        • Grindlay K
        • Lane K
        • Grossman D.
        Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study.
        Womens Health Issues. 2013; 23: e117-e122
        • Ehrenreich K
        • Kaller S
        • Raifman S
        • Grossman D.
        Women's experiences using telemedicine to attend abortion information visits in Utah: a qualitative study.
        Womens Health Issues. 2019; 29: 407-413
      1. Mifepristone. Approved Risk Evaluation and Mitigation Strategies (REMS) 2019.

        • Raymond EG
        • Blanchard K
        • Blumenthal PD
        • Cleland K
        • Foster A
        • Gold M
        • et al.
        Sixteen years of overregulation: time to unburden Mifeprex.
        N Engl J Med. 2017; 376: 790-794
        • Bearak JM
        • Burke KL
        • Jones RK.
        Disparities and change over time in distance women would need to travel to have an abortion in the USA: a spatial analysis.
        Lancet Public Health. 2017; 2: e493-e500
        • Perreira KM
        • Johnston EM
        • Shartzer A
        • Yin S.
        Perceived access to abortion among women in the United States in 2018: variation by state abortion policy context.
        Am J Public Health. 2020; 110: 1039-1045
      2. Investigational New Drug (IND) Application. U.S. Food and Drug Administration; 2021.

        • Raymond E
        • Chong E
        • Winikoff B
        • Platais I
        • Mary M
        • Lotarevich T
        • et al.
        TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
        Contraception. 2019; 100: 173-177
        • Chong E
        • Shochet T
        • Raymond E
        • Platais I
        • Anger H
        • Raidoo S
        • et al.
        Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
        Contraception. 2021; (In press)
        • Schreier M
        Qualitative content analysis.
        (editor.)in: Flick U The SAGE handbook of qualitative data analysis. SAGE Publications, London, United Kingdom2013
        • Vaismoradi M
        • Jones J
        • Turunen H
        • Snelgrove S.
        Theme development in qualitative content analysis and thematic analysis.
        J Nurs Educ. 2016; 6: 100-110
        • Levesque J-F
        • Harris MF
        • Russell G.
        Patient-centred access to health care: conceptualising access at the interface of health systems and populations.
        Int J Equity Health. 2013; 12: 18
        • Jerman J
        • Frohwirth L
        • Kavanaugh ML
        • Blades N.
        Barriers to abortion care and their consequences for patients traveling for services: qualitative findings from two states.
        Perspect Sex Reprod Health. 2017; 49: 95-102
        • Aiken ARA
        • Broussard K
        • Johnson DM
        • Padron E.
        Motivations and experiences of people seeking medication abortion online in the United States.
        Perspect Sex Reprod Health. 2018; 50: 157-163